A versatile modular vector system for rapid combinatorial mammalian genetics

The Journal of Clinical Investigation
Joachim AlbersIan J Frew

Abstract

Here, we describe the multiple lentiviral expression (MuLE) system that allows multiple genetic alterations to be introduced simultaneously into mammalian cells. We created a toolbox of MuLE vectors that constitute a flexible, modular system for the rapid engineering of complex polycistronic lentiviruses, allowing combinatorial gene overexpression, gene knockdown, Cre-mediated gene deletion, or CRISPR/Cas9-mediated (where CRISPR indicates clustered regularly interspaced short palindromic repeats) gene mutation, together with expression of fluorescent or enzymatic reporters for cellular assays and animal imaging. Examples of tumor engineering were used to illustrate the speed and versatility of performing combinatorial genetics using the MuLE system. By transducing cultured primary mouse cells with single MuLE lentiviruses, we engineered tumors containing up to 5 different genetic alterations, identified genetic dependencies of molecularly defined tumors, conducted genetic interaction screens, and induced the simultaneous CRISPR/Cas9-mediated knockout of 3 tumor-suppressor genes. Intramuscular injection of MuLE viruses expressing oncogenic H-RasG12V together with combinations of knockdowns of the tumor suppressors cyclin-depende...Continue Reading

References

Oct 10, 1998·Journal of Virology·T DullL Naldini
Jun 23, 1999·Oncogene·G C Prendergast
Oct 9, 2001·Human Gene Therapy·M KumarR E Sutton
Sep 8, 2005·Nature Methods·Patrick J PaddisonGregory J Hannon
Sep 9, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Olivier ter BrakeBen Berkhout
Feb 8, 2007·Proceedings of the National Academy of Sciences of the United States of America·Michaela GruberM Celeste Simon
May 30, 2007·The Journal of Gene Medicine·Nadya al YacoubJohn Foerster
Jan 9, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Olivier ter BrakeBen Berkhout
Jul 2, 2008·Neoplasia : an International Journal for Oncology Research·Stefan K SiwkoYi Li
Aug 15, 2009·Genes, Chromosomes & Cancer·Simone MartinelliCarlo Dominici
Aug 21, 2009·Nature Reviews. Cancer·Ran Brosh, Varda Rotter
Oct 5, 2010·The American Journal of Pathology·Gaëlle PérotAlain Aurias
Nov 17, 2010·Genes & Development·Thomas KuilmanDaniel S Peeper
Jul 19, 2011·Nature Biotechnology·Grigory S FilonovVladislav V Verkhusha
Dec 3, 2011·Proceedings of the National Academy of Sciences of the United States of America·Simone HettmerAmy J Wagers
Dec 7, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Neerav ShuklaMarc Ladanyi
Jan 4, 2012·Angewandte Chemie·Grigory S FilonovVladislav V Verkhusha
Feb 14, 2012·Nature Cell Biology·Yifeng XiaInder M Verma
Oct 23, 2012·Science·Dinorah Friedmann-MorvinskiInder M Verma
Jan 31, 2013·Nature Biotechnology·Woong Y HwangJ Keith Joung
Apr 1, 2007·Expert Opinion on Drug Discovery·Federico Katzen
Apr 23, 2013·EMBO Molecular Medicine·Joachim AlbersIan J Frew
Jul 31, 2013·Nature Methods·Morgan L MaederJ Keith Joung
Sep 28, 2013·Nature Genetics·Giovanni CirielloChris Sander
Dec 4, 2013·Genes & Development·Abba MalinaJerry Pelletier
Dec 18, 2013·Cancer Cell·Xiang ChenUNKNOWN St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project
Mar 4, 2014·Nature Biotechnology·Jeffry D Sander, J Keith Joung
Apr 29, 2014·Nature Biotechnology·Shengdar Q TsaiJ Keith Joung

❮ Previous
Next ❯

Citations

Oct 29, 2015·Critical Reviews in Biochemistry and Molecular Biology·Erik Serrao, Alan N Engelman
Jul 3, 2015·Cell & Bioscience·Sean M RiordanShui Qing Ye
Jun 7, 2016·Theriogenology·Pei-Hsun ChengShang-Hsun Yang
Dec 8, 2017·Nature Communications·Gaetana RestivoLukas Sommer
Dec 28, 2018·Nucleic Acids Research·Jonathan M HaldemanChristopher B Newgard
Jun 22, 2019·Cancer Gene Therapy·Jishnu NairDwaipayan Sen
May 19, 2019·RNA·Megan D SchertzerJ Mauro Calabrese
Aug 30, 2019·International Journal of Cancer. Journal International Du Cancer·Vivien FreihenAndreas Hecht
Jun 20, 2019·PloS One·Fangfang SunEmmanuel Karouzakis
Nov 15, 2017·Nature Communications·Ana Filipa GonçalvesIan J Frew
Apr 2, 2020·Frontiers in Chemistry·Silvia Pomella, Rossella Rota
Jun 28, 2015·Oncotarget·Ian J Frew
Jul 4, 2019·The EMBO Journal·Verena PaulitschkeMitchell P Levesque
Mar 11, 2020·Nature Communications·Nicholas S McCartyRodrigo Ledesma-Amaro
Nov 1, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrea L CasillasNoel A Warfel
Oct 30, 2020·Frontiers in Immunology·Mohammadreza Azangou-KhyavyJafar Kiani
Feb 3, 2021·Trends in Biotechnology·Roberto Di BlasiFrancesca Ceroni
Oct 30, 2020·International Journal of Molecular Sciences·Meike DahlhausPamela Fischer-Posovszky
Nov 5, 2019·Clinical Oncology : a Journal of the Royal College of Radiologists·J StewartC J Lord
Sep 5, 2021·Molecular Metabolism·D HalbgebauerD Tews

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
Destination
xenograft
gene knockout
xenografts
electron microscopy
transgenic
FCS
PCR
electrophoresis

Software Mentioned

Living Image
MuLE Entry
MuLE
MultiSite

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR Screens in Drug Resistance (ASM)

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Virology & CRISPR

This feed focuses on the virology of CRISPR and its use in developing CRISPR-Cas systems. Discover the latest research here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.

CRISPR in Cancer

CRISPR-Cas system enables the editing of genes to create or correct mutations. Given that genome instability and mutation is one of the hallmarks of cancer, the CRISPR-Cas system is being explored to genetically alter and eliminate cancer cells. Here is the latest research.